BiotechTube

Vatiquinone

Pre-clinicalActive
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mitochondrial Disease

Conditions

Mitochondrial Disease

Trial Timeline

— → —

NCT ID
NCT07159139

About Vatiquinone

Vatiquinone is a pre-clinical stage product being developed by PTC Therapeutics for Mitochondrial Disease. The current trial status is active. This product is registered under clinical trial identifier NCT07159139. Target conditions include Mitochondrial Disease.

What happened to similar drugs?

0 of 1 similar drugs in Mitochondrial Disease were approved

Approved (0) Terminated (0) Active (1)
🔄VatiquinonePTC TherapeuticsPhase 3

Hype Score Breakdown

Clinical
3
Activity
12
Company
12
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT07159139Pre-clinicalActive
NCT05515536Phase 3Active
NCT05485987Phase 2Completed
NCT05218655Phase 3Completed
NCT04378075Phase 2/3Terminated

Competing Products

13 competing products in Mitochondrial Disease

See all competitors
ProductCompanyStageHype Score
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mgAbbViePhase 2
35
Cysteamine BitartrateAmgenPhase 2
27
Cysteamine BitartrateAmgenPhase 2
35
VatiquinonePTC TherapeuticsPhase 2/3
27
EPI-743PTC TherapeuticsPre-clinical
23
RG2133 (2',3',5'-tri-O-acetyluridine)RepligenPhase 1
18
VatiquinonePTC TherapeuticsPhase 3
37
Oral administration of 100 mg KH176 twice dailyCertaraPhase 2
29
Sonlicromanol + PlaceboCertaraPhase 2
33